

**First-in-Human Telerobotic Coronary Intervention Procedures Published in
*The Lancet Journal, EClinicalMedicine***

*Renowned medical journal publishes the successful clinical results of remote PCI procedures using
CorPath® GRX Robotic System technology*

WALTHAM, Mass., September 3, 2019 -- [Corindus Vascular Robotics, Inc.](http://www.corindus.com) (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that *EClinicalMedicine*, a clinical journal published by the nearly 200-year-old medical journal *The Lancet*, has published the results from the [Telerobotic Intervention Study](#), the world’s first percutaneous coronary intervention (PCI) procedures conducted from a remote location outside the catheterization lab using Corindus’ CorPath technology platform.

The paper, titled *Long Distance Telerobotic-Assisted Percutaneous Coronary Intervention: First-in-Human Experience*, discusses five successful patient cases performed by internationally acclaimed physician Dr. Tejas Patel, Chairman and Chief Interventional Cardiologist of the Apex Heart Institute in Ahmedabad, Gujarat, India. The five patients featured in the paper underwent elective PCI procedures from a distance of approximately 20 miles (32 kilometers) from Dr. Patel’s location inside the Swaminarayan Akshardham Temple in Gandhinagar, Gujarat, India. His partner, Dr. Sanjay Shah, was onsite in the room with each patient at the Apex Heart Institute.

“I am honored to have been a part of this medical milestone,” stated Dr. Patel. “The application of telerobotics for remote treatment has the potential to impact a significant number of lives by providing access to specialized care that may not otherwise be possible. I am pleased to share my experience with the clinical community in such a well-respected publication that is part of the *Lancet* family,” added Dr. Patel.

To improve patient outcomes and broaden access to high-level care, Corindus has pioneered the world’s first remote telerobotic interventional platform to deliver highly specialized and timely cardiovascular care to underserved patient populations with geographic barriers to treatment. The Company is working on product development to enable use of the CorPath System in remote interventions and expand the Company’s robotic platform to address stroke care.

“Remote procedures have the potential to transform how we deliver care when treating the most time-sensitive illnesses such as heart attack and stroke. The success of this study paves the way for large-scale, long-distance telerobotic platforms across the globe, and its publication in *Lancet’s EClinicalMedicine* demonstrates the transformative nature of telerobotics,” said Mark Toland, President and Chief Executive Officer of Corindus Vascular Robotics. “While remote robotic procedures are still in the early stages of development, it is clear we are on track to expand patients’ access to care, while reducing their time to treatment,” Toland concluded.

To learn more about Corindus and CorPath GRX, please visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied

by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates," "should" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control.

Examples of such statements include statements regarding or such as:

- The Company's ability to use the CorPath System in remote interventions and expand the Company's robotic platform to address stroke care;
- That the application of telerobotics for remote treatment has the potential to impact a significant number of lives by providing access to specialized care that may not otherwise be possible;
- That remote procedures have the potential to transform how we deliver care when treating the most time-sensitive illnesses such as heart attack and stroke; and
- That the Company is on track to expand patients' access to care, while reducing their time to treatment.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as Current Reports on Form 8-K, including, but not limited to, the following: the risk that the required vote of Corindus' stockholders will not be received; the risk that one or more conditions to the proposed merger (including the failure to obtain necessary regulatory approvals) may not be satisfied in the anticipated timeframe, or at all, or that the proposed merger might otherwise not occur; the risk of litigation and/or regulatory actions related to the proposed merger; other business effects, including the effects of industry, market, economic, political or regulatory conditions; our ability to expand our technology platform and achieve the advances necessary for telestenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries, including for stroke and other neurovascular interventions; the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward-looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at www.corindus.com.

For more information, contact:

Media Contact:

Matter for Corindus
Jill Gross
corindus@matternow.com
www.matternow.com

Investor Contact:

In-Site Communications, Inc.
Lisa Wilson
917-543-9932
ir@corindus.com